Drug delivery systems (DDS) play a crucial role in efficiently targeting drugs to specific diseased tissues with minimal side effects. Recent advancements have highlighted the significance of DDS in enhancing drug bioavailability and reducing side effects through optimal formulations. Mesoporous silica DDS (MS-DDS) has emerged as a promising carrier due to its sustained release capabilities and high drug solubility. However, concerns regarding toxicity and long-term accumulation with synthetic MS-DDS have shifted focus towards natural alternatives like biosilica from diatoms. Biosilica offers a natural and biocompatible DDS platform with the ease of cultivation and simple extraction processes, making it an attractive option for drug delivery applications.
In the realm of chemotherapy, the development of effective drug formulations with improved bioavailability and reduced side effects is paramount. DDS studies aim to overcome physiological barriers and deliver drugs effectively through various delivery systems. MS-DDS, particularly biosilica derived from diatoms, has gained attention for its unique nanoporous structure and controlled drug release properties. This natural carrier presents opportunities for developing oral DDS platforms that offer sustained release benefits and low cytotoxicity, addressing key challenges in drug administration.
The application of MS-DDS platforms, including biosilica, extends across multiple administration routes such as oral, transdermal, rectal, and injectable methods. Oral drug delivery studies have demonstrated the sustained release capabilities and low cytotoxicity of biosilica, showcasing its potential in enhancing drug bioavailability. Additionally, biosilica has shown promise in transdermal drug delivery systems, where functionalized MSNs have been utilized for efficient drug permeation through the skin. Moreover, biosilica-based DDS platforms have exhibited effective hemostatic and wound healing properties, underlining their versatility in diverse medical applications.
While biosilica holds great promise as a natural DDS carrier, challenges remain in its application through injection routes. Concerns regarding biosilica accumulation in vital organs post-injection warrant a thorough evaluation of its biodegradability and cytotoxicity. Despite these challenges, ongoing research aims to validate the safety and biocompatibility of MS-DDSs, including biosilica, through comprehensive in vivo studies. Strategic advancements in biosilica-based DDS platforms offer a viable alternative to synthetic carriers, with the potential to revolutionize drug delivery systems by combining sustained release benefits with natural biocompatibility.
Key Takeaways:
– Biosilica from diatoms presents a natural and sustainable alternative to synthetic MS-DDS for drug delivery applications.
– The unique nanoporous structure of biosilica enables controlled drug release and low cytotoxicity, making it an ideal candidate for oral and transdermal DDS platforms.
– Ongoing research focuses on addressing challenges related to biosilica accumulation post-injection and validating its biodegradability and safety through in vivo studies.
– Strategic advancements in biosilica-based DDS platforms hold the potential to revolutionize drug delivery systems by combining sustained release benefits with natural biocompatibility.
Tags: drug delivery, formulation, lipid nanoparticles
Read more on pmc.ncbi.nlm.nih.gov